Haematologica (Aug 2023)
Myeloid lineage switch in <i>KMT2A-</i>rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies
- Alex Bataller,
- Tareq Abuasab,
- David McCall,
- Wei Wang,
- Branko Cuglievan,
- Ghayas C. Issa,
- Elias Jabbour,
- Nicholas Short,
- Courtney D. DiNardo,
- Guilin Tang,
- Guillermo Garcia-Manero,
- Hagop M. Kantarjian,
- Koji Sasaki
Affiliations
- Alex Bataller
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Tareq Abuasab
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- David McCall
- Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
- Wei Wang
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
- Branko Cuglievan
- Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
- Ghayas C. Issa
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Elias Jabbour
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Nicholas Short
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Courtney D. DiNardo
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Guilin Tang
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
- Guillermo Garcia-Manero
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Hagop M. Kantarjian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- Koji Sasaki
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- DOI
- https://doi.org/10.3324/haematol.2023.283705
- Journal volume & issue
-
Vol. 109,
no. 1
Abstract
No abstracts available.
